Foundations of Hormone Replacement Therapy

The premise

Hormone replacement therapy sits in a long-running argument between two camps: one that extrapolates the WHI findings to every form of hormone therapy, and one that distinguishes bioidentical hormones from the synthetic analogs WHI actually studied. Nimbus practices in the second camp — but with a discipline the first camp rarely sees in the wild: every clinical claim is cited, every protocol is documented, every prescription is defensible.

This module establishes the shared language and reasoning everyone on the Nimbus clinical team uses. The seven modality modules that follow (Module 01 — Estrogen, Module 02 — Progesterone, Module 03 — Testosterone in women, Module 04 — Testosterone in men, Module 05 — Thyroid, Module 06 — DHEA / Melatonin, Module 07 — Clinical practice) assume you've internalized it.

Anchor — what did WHI actually study?

The bioidentical / synthetic distinction

Bioidentical

17β-estradiol (E2)

WHI estrogen

Equilin (CEE representative)

Synthetic

Ethinyl estradiol

WHI progestin

MPA (Provera)

A bioidentical hormone is structurally identical to a hormone the human body produces — estradiol (E2), progesterone, testosterone, T3, T4, DHEA. A synthetic analog (conjugated equine estrogens, medroxyprogesterone acetate, ethinyl estradiol, levonorgestrel) is not. The pharmacology is different, the receptor binding is different, and — critically — the safety data does not transfer.

The Women's Health Initiative^[WHI-2002] studied conjugated equine estrogens (Premarin) + medroxyprogesterone acetate (Provera). Its findings — increased breast cancer, CHD, stroke, VTE — apply to that specific combination. The E3N (EPIC) cohort^[E3N-2008] directly compared bioidentical hormone replacement therapy (BHRT) and synthetic regimens in 80,377 French women: estradiol with bioidentical progesterone produced a relative risk of 1.00 for breast cancer; estradiol with synthetic progestins produced relative risks of 1.16–1.69. The route mattered less than the molecule.

Study design before claims — the evidence hierarchy

Interpreting the HRT literature requires holding a discipline most consult notes do not: distinguish association from causation by the design of the trial that produced the number. The hierarchy that anchors every Nimbus claim:

1. Randomized controlled trial (RCT) — experimental, can show causation. DOPS, PEPI, HERS, WHI, KEEPS, ELITE, REPLENISH, TRAVERSE.
2. Prospective cohort — observational, generates associations. E3N (EPIC), Nurses' Health Study.
3. Case-control — observational, narrower scope. CORA.
4. Cross-sectional / retrospective chart review — observational, hypothesis-generating only.

Two implications follow. First, the E3N relative risks for bioidentical vs. synthetic progestogen partners are associations from a prospective cohort — strong, biologically plausible, internally consistent across analyses, but not RCT-grade causation. Second, the WHI hazard ratios are causal claims from a randomized trial — but for the specific molecules and specific population studied (mean age 63, median 12 years postmenopause, oral CEE + MPA). Both pieces of evidence are real; neither can be substituted for the other.

Landmark studies — the citation-grade tour

The studies below are the citations every Nimbus modality module quotes. Internalize them in this order. Each gets one paragraph here; the modality modules expand the ones that matter for their domain.

Nurses' Health Study (NHS, 1976). The observational cohort that anchored two generations of hormone-and-cancer epidemiology. 121,700 female nurses aged 30–55, mailed questionnaires every 2 years, follow-up extending decades. Found increased breast cancer, CHD (primarily in smokers), and stroke with oral contraceptives; reduced colon cancer; and a cardioprotective signal for HRT initiated soon after menopause — relative risk of death 0.63 for current hormone users vs. never users in the 30–53 estrogen substudy. The hormones in question were synthetic contraceptives and conjugated estrogens, not bioidentical E2 + progesterone — a distinction the headlines never made.^[NHS-1976]

PEPI Trial (1997). RCT, 875 healthy postmenopausal women aged 45–64, four hormone regimens vs. placebo. The CEE-only arm showed higher rates of endometrial hyperplasia; the bioidentical micronized progesterone arm provided endometrial protection equivalent to MPA. HRT improved lipid profiles and glucose metabolism, but the trial was not powered for clinical CV events. PEPI is the trial that established bioidentical progesterone as endometrially protective in its own right — the foundation Module 02 — Progesterone builds on.^[PEPI-1995]

HERS (1998). Secondary-prevention RCT, 2,763 postmenopausal women aged 44–79 with established CHD, CEE 0.625 mg + MPA 2.5 mg vs. placebo for ~4.1 years. No overall CHD-event benefit; early signal of increased CHD events in year 1; reduced events in years 4–5. HERS concluded that synthetic HRT should not be used for secondary CHD prevention. The Nimbus reading: HERS is a study of CEE+MPA in women with prevalent coronary disease — it does not refute the case for early-initiation bioidentical estradiol in primary prevention.^[HERS-1998]

Danish Osteoporosis Prevention Study (DOPS, 2012). 2,016 women aged 45–58, oral 17-beta-estradiol +/- norethisterone, recently postmenopausal at randomization. At 10 years the randomized arm showed significantly lower mortality, heart failure, and myocardial infarction — with no increase in cancer, VTE, or stroke. DOPS is the cleanest trial-grade evidence that oral E2-based HRT initiated near menopause reduces hard cardiovascular endpoints.^[DOPS-2012]

WHI — CEE + MPA arm (2002). The trial that drove a generation of HRT discontinuation. Two-arm RCT, 16,608 postmenopausal women aged 50–79 with intact uterus, oral CEE 0.625 mg + MPA 2.5 mg vs. placebo. Headline hazard ratios at publication: CHD 1.29, stroke 1.41, DVT 2.07, PE 2.13, invasive breast cancer 1.26. The trial was halted early. The 2002 publication emphasized non-statistically-significant findings to justify early termination, and post-hoc analyses have surfaced baseline risk-factor imbalance and undisclosed prior-HRT-use distribution between arms. The headline still shapes FDA labeling and consult-note language. The Nimbus reading: these hazard ratios apply to CEE+MPA in women a median of 12 years postmenopause — they do not generalize to bioidentical E2 + micronized progesterone, and they do not generalize to women initiating near menopause.^[WHI-2002]

WHI — estrogen-alone arm (2004). 10,739 postmenopausal women post-hysterectomy, CEE 0.625 mg vs. placebo, terminated early at 6.8 years for a perceived stroke signal. Reported hazard ratios: CHD 0.91, breast cancer 0.77, stroke 1.39, hip fracture 0.61. The breast-cancer signal trended down on estrogen alone — a finding routinely omitted in the public memory of WHI. Post-analysis: decreased breast-cancer and fracture benefits persisted; the stroke risk attenuated over time. The estrogen-alone arm is the piece of WHI that, when read on its own terms, supports estrogen replacement in hysterectomized women.^{[WHI-CEE-2004]}

E3N (EPIC) cohort (2008). French prospective cohort, 80,377 postmenopausal women aged 40–65, mean follow-up 8.1 years. Breast-cancer relative risks broke down by progestogen partner: E2 + bioidentical progesterone RR 1.00; E2 + dydrogesterone roughly RR 1.00; E2 + synthetic progestins RR 1.16–1.69; CEE-alone RR 1.29. Route of estrogen (oral vs. transdermal) did not change the breast-cancer signal; the progestogen type did. E3N is the cornerstone study for the bioidentical / synthetic distinction in Module 01 — Estrogen and Module 02 — Progesterone.^[E3N-2008]

KEEPS (2014). RCT, 727 recently menopausal women (≤3 years postmeno) aged 42–58. Three arms: low-dose oral CEE 0.45 mg/day + cyclic oral progesterone 200 mg 12 days/month, transdermal E2 patch 50 mcg/day + same P4, placebo. No carotid intima-media thickness difference at 4 years, but oral CEE reduced coronary-artery calcium accumulation. Both hormone arms reduced vasomotor symptoms and maintained bone density. KEEPS used CEE rather than bioidentical oral E2 and a 4-year horizon — likely too short for a full cardiovascular signal — but established the safety of early-meno initiation.^[KEEPS-2014]

ELITE (2016). RCT, 643 postmenopausal women in two strata — early postmenopause (<6 years) and late postmenopause (≥10 years). 1 mg oral E2 daily + vaginal P4 gel 4% 10 days/cycle vs. placebo, average 5-year follow-up. The early-postmenopause group showed statistically significant reduction in CIMT progression; the late group did not. No CAC differences. Oral E2 was safe — no MI or plaque rupture observed. ELITE operationalizes the "window of opportunity" for atherosclerosis prevention with oral bioidentical estradiol (see Module 01 — Estrogen for the full window framing).^[ELITE-2016]

ELITE-Cog (2016 companion). The cognitive substudy of ELITE separately reported on verbal memory and executive function in the same 643 women. The headline: oral estradiol did not impair cognition in either the early or late stratum, and the early stratum had small numerical advantages on several cognitive measures that did not reach statistical significance at the 5-year mark. ELITE-Cog is the citation that lets a Nimbus prescriber defend oral E2 in cognitively concerned patients — it does not show cognitive benefit in late-postmeno women, but it refutes the claim of cognitive harm.^{[ELITE-Cog-2016]}

TRAVERSE (2023). RCT, 5,204 men aged 45–80 with clinical hypogonadism plus symptoms, all with preexisting cardiovascular disease or high CV risk. Testosterone 1.62% gel vs. placebo, ~21 months of treatment, ~33 months of follow-up. The headline: major adverse cardiovascular event (MACE) incidence was not increased. Higher rates of pulmonary embolism, atrial fibrillation, nonfatal arrhythmias, and acute kidney injury were observed but the study was not powered for causality on those secondary events. TRAVERSE led to the FDA removal of the MACE black-box on testosterone products and is the foundation of Module 04 — Testosterone in men.^{[TRAVERSE-2023]}

Lab interpretation across vendors

Quest and LabCorp don't always report the same hormone in the same units, and even when the units match, the assay precision and the "normal" ranges differ. Two principles:

1. Always know which vendor produced the result you're reading.
2. When converting, use the empirical factor — not assumed unit equivalence.

The clearest example: postmenopausal progesterone. Quest's chemiluminescent immunoassay reads roughly 3.5x higher than LabCorp's assay for the same serum sample. A Nimbus postmenopausal progesterone target of ≥10 ng/mL on Quest is the same biologic state as ≥3 ng/mL on LabCorp. The conversion is empirical and direction-aware: never assume the vendors are interchangeable, never report a Quest value against a LabCorp range or vice versa.

The vendor-aware mindset extends to every hormone in the Nimbus curriculum. Free testosterone in men reads 170–210 pg/mL (Quest) vs. 30–40 pg/mL (LabCorp) at the same biologic state (see Module 04 — Testosterone in men). Free T3 reference ranges also differ between vendors and assay platforms (see Module 05 — Thyroid).

Mid-module checkpoint — cross-vendor lab interpretation

The universal safety blocks

Hard contraindications gate any HRT initiation at Nimbus. The blocks below are universal across all seven modalities — they sit upstream of any modality-specific dose-laddering. The block, the rationale, and the escalation path are explicit:

1. Active prostate cancer. Testosterone replacement is blocked pending oncology clearance. Androgen-driven proliferation is the mechanism; survivorship status and castrate-resistant subtypes require specialist input (see Module 04 — Testosterone in men).
2. Active breast cancer. Estrogen replacement is blocked pending oncology clearance. ER/PR status matters; survivorship status matters; the decision is co-managed with the patient's oncology team (see Module 01 — Estrogen).
3. Pregnancy or lactation. DHEA is absolutely contraindicated (teratogenic potential). Testosterone is absolutely contraindicated. Estrogen and progesterone are deferred to obstetric management.
4. Active immunosuppressant therapy. Melatonin is absolutely contraindicated. Melatonin's immunomodulatory effects make it unsafe in patients on calcineurin inhibitors, mTOR inhibitors, or other transplant-stabilizing regimens (see Module 06 — DHEA / Melatonin).
5. PDE5 inhibitor + nitrates or riociguat. Severe hypotension risk — this is a hard block in patient counseling regardless of hormone modality. PDE5 co-prescribing for sexual function (often paired with TRT) requires explicit cardiovascular medication review.
6. Hy's Law liver injury (AST/ALT ≥3x ULN + total bilirubin ≥2x ULN). Hold all hormone therapy and escalate urgently to hepatology. The signal indicates serious hepatocellular injury and supersedes any titration decision.
7. Pituitary adenoma rule-out for low-T men with prolactin >40 ng/mL. TRT is deferred until pituitary work-up is complete. Prolactin elevation in a hypogonadal man can mask a prolactinoma; initiating TRT before evaluation can confound the diagnostic workup and delay neurosurgical referral (see Module 04 — Testosterone in men).

A secondary block — not absolute but practice-routine at Nimbus — is untreated severe obstructive sleep apnea (STOP-Bang positive). TRT initiation is deferred pending sleep evaluation; testosterone can worsen OSA, and the cardiovascular signal in untreated OSA plus TRT is unfavorable. This is a Nimbus-position block, not a universal contraindication, and is documented as such (see Module 04 — Testosterone in men).

Role-specific applied content

High-yield facts

Self-check — bioidentical / synthetic

Post-test — synthesis

Module evaluation